Floatz Rating
C39/100
Confidence
Indicative
Sponsor
Novartis Pharmaceuticals
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05544929CT.gov A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Mesothelioma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| kfa115 (this asset) | Novartis Pharmaceuticals | P1 | C · 39 |
| Cyclophosphamide | National Cancer Institute (NCI) | P2 | BB |
| Fludarabine | National Cancer Institute (NCI) | P2 | B |
| Nivolumab | Orion Corporation, Orion Pharma | P2 | B |
| Pembrolizumab | Genmab | P2 | B |
| Fludeoxyglucose | National Cancer Institute (NCI) | P2 | B |
| 18f-fspg | Andrei Iagaru | P2 | B |
| Irinotecan | Genmab | P1/2 | CCC |
| Tislelizumab | HiFiBiO Therapeutics | P2 | CCC |
+42 more in the Mesothelioma cohort
Other indications for kfa115
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Ovarian Carcinoma | — | P1 | CC · 43 |
| Renal Cell Carcinoma | — | P1 | CC · 43 |
| Thymic Carcinoma | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. kfa115 in Mesothelioma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/kfa115-mesothelioma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →